Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2026
Integrated psychosocial, sleep, and immunonutritional intervention improves psychological adaptation, sleep disturbance, and inflammatory activation in rectal cancer: a randomized controlled trial.
СтатьяРандомизированное исследованиеНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Pan Shengjie, Wang Gang
Аннотация
BACKGROUND: Patients undergoing abdominoperineal or intersphincteric resection for low rectal cancer experience profound physiological and psychological stress. Conventional Enhanced Recovery After Surgery (ERAS) protocols mainly address surgical and metabolic factors but rarely target the host's psychosocial and immunometabolic recovery.
STUDY DESIGN: In this single-center randomized controlled trial, 240 patients with stage II-III low rectal cancer (September 2019-September 2021) were randomized (1:1) to receive either standard ERAS care or an integrated perioperative intervention combining resilience-based psychosocial support, cognitive behavioral therapy for insomnia, and Prognostic Immune Nutritional Index (PINI)-guided nutritional optimization. The primary outcomes were global quality of life (EORTC QLQ-C30) and sleep quality (Pittsburgh Sleep Quality Index). The secondary outcomes included postoperative recovery, inflammatory and nutritional indices, and 3-year disease-free and overall survival.
RESULTS: At 12 months, the intervention group showed greater improvement in quality of life (mean difference = 12.3, 95% CI 8.6-16.0; p < 0.001) and sleep quality (-3.1, 95% CI -4.5 to -1.8; p < 0.001). Serum interleukin-6 declined more rapidly (-1.9 pg/mL vs -0.8; p < 0.001), accompanied by improved PINI (-0.7; p < 0.01) and higher fecal short-chain fatty acid levels (+ 10.6 mmol/kg; p < 0.001). Three-year disease-free survival favored the intervention (HR 0.69, 95% CI 0.51-0.93; p = 0.015). No intervention-related serious adverse events occurred.
CONCLUSIONS: Integrating psychosocial, sleep, and immunonutritional components into perioperative care enhanced functional and physiological recovery after low rectal cancer surgery. These findings support extending ERAS toward targeted modulation of host response to improve both short- and long-term outcomes.
STUDY DESIGN: In this single-center randomized controlled trial, 240 patients with stage II-III low rectal cancer (September 2019-September 2021) were randomized (1:1) to receive either standard ERAS care or an integrated perioperative intervention combining resilience-based psychosocial support, cognitive behavioral therapy for insomnia, and Prognostic Immune Nutritional Index (PINI)-guided nutritional optimization. The primary outcomes were global quality of life (EORTC QLQ-C30) and sleep quality (Pittsburgh Sleep Quality Index). The secondary outcomes included postoperative recovery, inflammatory and nutritional indices, and 3-year disease-free and overall survival.
RESULTS: At 12 months, the intervention group showed greater improvement in quality of life (mean difference = 12.3, 95% CI 8.6-16.0; p < 0.001) and sleep quality (-3.1, 95% CI -4.5 to -1.8; p < 0.001). Serum interleukin-6 declined more rapidly (-1.9 pg/mL vs -0.8; p < 0.001), accompanied by improved PINI (-0.7; p < 0.01) and higher fecal short-chain fatty acid levels (+ 10.6 mmol/kg; p < 0.001). Three-year disease-free survival favored the intervention (HR 0.69, 95% CI 0.51-0.93; p = 0.015). No intervention-related serious adverse events occurred.
CONCLUSIONS: Integrating psychosocial, sleep, and immunonutritional components into perioperative care enhanced functional and physiological recovery after low rectal cancer surgery. These findings support extending ERAS toward targeted modulation of host response to improve both short- and long-term outcomes.